Current File : //var/www/html/shaban/duassis/api/public/storage/admq/cache/cb995d1fc9ec0f0659382bbe35c63269
a:5:{s:8:"template";s:3196:"<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html lang="en">
<head profile="http://gmpg.org/xfn/11">
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<title>{{ keyword }}</title>
<style rel="stylesheet" type="text/css">@font-face{font-family:Roboto;font-style:normal;font-weight:400;src:local('Roboto'),local('Roboto-Regular'),url(https://fonts.gstatic.com/s/roboto/v20/KFOmCnqEu92Fr1Mu4mxP.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(https://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfBBc9.ttf) format('truetype')} html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}a{background-color:transparent}a:active,a:hover{outline:0}h1{margin:.67em 0;font-size:2em}/*! Source: https://github.com/h5bp/html5-boilerplate/blob/master/src/css/main.css */@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}p{orphans:3;widows:3}} *{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}h1{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}h1{margin-top:20px;margin-bottom:10px}h1{font-size:36px}p{margin:0 0 10px}@-ms-viewport{width:device-width}html{height:100%;padding:0;margin:0}body{font-weight:400;font-size:14px;line-height:120%;color:#222;background:#d2d3d5;background:-moz-linear-gradient(-45deg,#d2d3d5 0,#e4e5e7 44%,#fafafa 80%);background:-webkit-linear-gradient(-45deg,#d2d3d5 0,#e4e5e7 44%,#fafafa 80%);background:linear-gradient(135deg,#d2d3d5 0,#e4e5e7 44%,#fafafa 80%);padding:0;margin:0;background-repeat:no-repeat;background-attachment:fixed}h1{font-size:34px;color:#222;font-family:Roboto,sans-serif;font-weight:900;margin:20px 0 30px 0;text-align:center}.content{text-align:center;font-family:Helvetica,Arial,sans-serif}@media(max-width:767px){h1{font-size:30px;margin:10px 0 30px 0}} </style>
<body>
</head>
<div class="wrapper">
<div class="inner">
<div class="header">
<h1><a href="#" title="{{ keyword }}">{{ keyword }}</a></h1>
<div class="menu">
<ul>
<li><a href="#">main page</a></li>
<li><a href="#">about us</a></li>
<li><a class="anchorclass" href="#" rel="submenu_services">services</a></li>
<li><a href="#">contact us</a></li>
</ul>
</div>
</div>
<div class="content">
{{ text }}
<br>
{{ links }}
</div>
<div class="push"></div>
</div>
</div>
<div class="footer">
<div class="footer_inner">
<p>{{ keyword }} 2021</p>
</div>
</div>
</body>
</html>";s:4:"text";s:20241:"15 minutes. COMPANY PROFILES 14.1 Aleta BioTherapeutics 14.1.1 Atela's Pipeline 14.2 Allogene Therapeutics 14.2.1 AlloCAR-T Therapy 14.3 Anixa Biosciences, Inc. 14.4 Atara Biotherapeutics Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus … More about Atara Bio . The Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel (tab … ... Atara Biotherapeutics has a market capitalisation of US$1.1b and burnt through US$242m last year, which is … ATRA: Atara Biotherapeutics, Inc. - Earnings Announcements. Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Equities research analysts predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will announce sales of $6.32 million for the current fiscal quarter, Zacks reports. Earnings analysis for Atara Biotherapeutics Inc. [ATRA] With the latest financial reports released by the company, Atara Biotherapeutics Inc. posted -1.36/share EPS, while the average EPS was predicted by analysts to be reported at -1.34/share. View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel ® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Download as PDF March 14, 2021 4:00pm EDT Atara Biotherapeutics Inc (. Financial ratios and metrics for Atara Biotherapeutics stock (ATRA). The stock has traded between $16.04 and $17.19 so far today. HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES. 5 Beaten-Down Biotech Stocks Set to Rebound in 2020. Atara Biotherapeutics Inc (ATRA) stock is trading at $15.29 as of 2:40 PM on Friday, May 14, an increase of $0.57, or 3.87% from the previous closing price of $14.72. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. See Atara Biotherapeutics, Inc. (ATRA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Atara Biotherapeutics, Inc.(@Atarabio)is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Atara Biotherapeutics Inc operates in the United States healthcare sector. Atara Biotherapeutics Inc is a clinical-stage biopharmaceutical company. SUBPLOT. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Equities research analysts predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will announce sales of $6.32 million for the current fiscal quarter, Zacks reports. The consensus estimate was a loss of $0.93 per share on revenue of $1.6 million. MarketBeat just released five new stock ideas, but Atara Biotherapeutics wasn't one of them. Atara Biotherapeutics Valuation Module provides a unique way to ballpark how much the company is worth today. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging … SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent … Monday, June 07, 2021 Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021. +0.31 (+2.21%) DATA AS OF May 20, 2021. ETFs Holding ATRA. The Company is focused on developing therapies for patients with severe and life-threatening diseases. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel … Atara Biotherapeutics Inc operates in the United States healthcare sector. As at December 2020, Atara Biotherapeutics had cash of US$501m and no debt. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Atara Biotherapeutics Inc (NASDAQ:ATRA) On Monday December 14, 2015 shares of Atara Biotherapeutics tanked 37% after the company reported that … Add to Watchlist. Three analysts have provided estimates for Atara Biotherapeutics' earnings, with estimates ranging from $4.10 million to $8.87 million. DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Nasdaq 100. The analysts price targets range from a … Corneal Ulcer Pipeline report offers a rich analysis of 6+ key pharma companies and 6+ key therapies. Strategic Management Essays, Term Papers & Presentations . A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the fourth quarter and full year … 13.04M. ... Atara Biotherapeutics headquarters is located at Building 83, 611 Gateway Blvd #900, South San Francisco. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus … Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting. About DelveInsight. Statistical analysis of some significant economics facts; Figures, charts, graphs, pictures to … Porter Five Forces Analysis is a strategic management tool to analyze industry and understand underlying levers of profitability in a given industry. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent … The shares are priced at $27.26, and the $50.14 average price target suggests ~84% one-year upside. Volatility Prediction for Wednesday, May 26th, 2021: 60.12% (-0.51%) COMPARE. Atara Biotherapeutics Inc APARCH Volatility Analysis. Does Atara Biotherapeutics Have A Long Cash Runway? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Some of the key pointers from the Corneal Ulcer Pipeline report:. Application. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. CAR-T Therapy Treatment Market report such as new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions can be utilized well by the Industry to take better steps for selling goods and services.This industry document forecasts the size of the market with information on key vendor revenues, development of the industry by upstream and downstream, … Atara Biotherapeutics Inc (NASDAQ: ATRA) has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel (tab-cel) in... Atara Biotherapeutics … Manher (AJ) Joshi was appointed to the role of Atara Biotherapeutics’ Chief Medical Officer in September 2018. Analyses | Docs. Lymphoproliferative Disorder Treatment Market Size, Growth, Trends and Global Segments Analysis Report to 2028 AmericaNewsHour. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our off-the-shelf, allogeneic T cells are bioengineered from donors with healthy immune function and allow for rapid delivery to patients. SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) 611 GATEWAY BLVD SOUTH SAN FRANCISCO, CA 94080. Add to Portfolio. Data is currently not available. Atara Biotherapeutics, Inc. ... analysis from three clinical studies of tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-driven post-transplant … $14.35. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to … Tab-cel®, Atara's most advanced T-cell immunotherapy in development, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported financial results for the second quarter ended June … Bring vital solutions to a world with vital needs. Analysis of the different market segments such as type, size, applications, and end-users. Atara Biotherapeutics Inc (ATRA) stock is trading at $16.25 as of 12:09 PM on Wednesday, Mar 3, a decline of -$0.69, or -4.07% from the previous closing price of $16.94. Wall Street analysts have given Atara Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Atara Biotherapeutics Inc. ATA190, developed using Atara’s complementary T-cell immunotherapy technology from QIMR Berghofer, has the potential to precisely recognize and eliminate EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology. Prior to joining Atara, he served as the Chief Medical Officer at Gossamer Bio, overseeing global development, regulatory, and quality activities for the company, and advancing therapeutics in the disease areas of immunology, inflammation, and oncology. Dr. Dupont is committed to bringing transformative therapies to patients. Company Releases for Atara Biotherapeutics Inc. Tuesday, June 08, 2021. On Wednesday, Atara Biotherapeutics earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 74. During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 0.98 million, with the beta value of the company hitting 2.43. 13. Volatility analysis of Atara Biotherapeutics Inc using a APARCH model. SOUTH SAN FRANCISCO, Calif.- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long-term overall survival (OS) analysis from … Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Go. At the end of the trading day, the stock’s price was $14.26, reflecting an intraday gain of 3.33% or $0.46. Barron's also provides information on historical stock ratings, … Three analysts have issued estimates for Atara Biotherapeutics' earnings. Net Cash. The Company operates through the business of developing and commercializing therapeutics segment. We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Apr 27 2021 Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Mar 14 2021 Dec-18-19 07:59AM. The stock has traded between $14.17 and $15.35 so far today. Stay up to date with lastest Earnings Announcements for Atara Biotherapeutics, Inc. from Zacks Investment Research Demonstrated ability to perform data analysis and effectively communicate results internally. Atara Biotherapeutics, Inc. Common Stock (ATRA) Nasdaq Listed. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. See our latest analysis for Atara Biotherapeutics . Volume today is below average. It focuses on developing therapeutics for patients with serious life-threatening such … Atara Biotherapeutics, Inc. (ATRA) is a South San Francisco based allogenic T-cell immunotherapy concern focused on the development of novel treatments for … Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting - read this article along with other careers information, tips and advice on BioSpace The lowest sales estimate is $4.10 million and the highest i So far 362,873 shares have traded compared to average volume of 860,664 shares. Model Dataset. ATRA: Atara Biotherapeutics, Inc. broker reports. Brokerages expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to announce $6.32 million in sales for the current quarter, according to Zacks Investment Research. Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. About Atara Biotherapeutics. Zacks. a Tier 4development firm based out of San Francisco. Atara Biotherapeutics Inc Add to Watchlists. MARKET ANALYSIS. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the presentation of data supporting the proposed mechanism of action of their lead … Volume today is light. Atara Biotherap (ATRA) reported a 1st Quarter March 2021 loss of $0.86 per share on revenue of $3.6 million. Volatility Analysis. V-Lab. Create an Alert Quickflows 19.53 +1.48 +8.20% NASDAQ Nov 16, 20:00 USD. Cash & Cash Equivalents. ATRA on StockCharts.com. Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others. Includes annual, quarterly and trailing numbers with full history and charts. Atara Biotherapeutics Inc. provides health care services. Demonstrated ability to maintain detailed lab execution records and perform data analysis. Tab-cel®, Atara's most advanced T-cell immunotherapy in development, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Detailed financial statements for Atara Biotherapeutics stock (ATRA), including the income statement, balance sheet, and cash flow statement. ATA188, developed using Atara’s T-cell immunotherapy technology from QIMR Berghofer, has the potential to target EBV-infected cells associated with MS pathophysiology. Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by stock analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a research note issued on Wednesday, Benzinga reports. We are considered a leading off-the-shelf T-cell immunotherapy company (Nasdaq ATRA) developing novel treatments for patients with cancer, autoimmune and viral diseases. So far 564,200 shares have traded compared to average volume of 996,159 shares. Atara Biotherapeutics (ATRA) - DEVELOPS THERAPEUTICS FOR MUSCLE-WASTING CONDITIONS AND ONCOLOGY. ATRA. ) We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases. The 52-week high for the ATRA The brokerage currently has a $29.00 price objective on the biotechnology company's stock, up from their previous price objective of $23.00. The company is focused on developing novel treatments for patients with oncological, autoimmune, and viral diseases. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. It is developing tabelecleucel... Company Analysis and Financial Data Status Unless specified all financial data is based on a yearly period but updated quarterly. He joined Atara in August 2016, initially serving as Senior Vice President, Global Medical Affairs. What's on this page? The Company is focused on developing therapies for patients with severe and life-threatening diseases. Quote; Fundamental Chart ... insightful view into how analysts view a company's prospects. Technical Operations (Tech Ops) within Atara Biotherapeutics offers a chance to help deliver breakthrough treatments that can make a positive difference for patients with serious illnesses. The summary for Atara Biotherapeutics, Inc. is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Eric Hyllengren - Vice President of Investor Relations and Finance. Get the latest broker reports from Zacks Investment Research. You’ll have the opportunity to achieve greatness and be empowered to make important things possible. 14. Balance Sheet. The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Atara Biotherapeutics, with an average price target of $44.75. Related Sites | V-Lab. Conference Call and Webcast Today at 4:30 p.m. EDT. If you are looking for stocks with good return, Atara Biotherapeutics Inc stock can be a bad, high-risk 1-year investment option. Technical analysis gauges display real-time ratings for the selected timeframes. Three analysts have issued estimates for Atara Biotherapeutics' earnings. ";s:7:"keyword";s:30:"atara biotherapeutics analysis";s:5:"links";s:720:"<a href="https://api.duassis.com/storage/admq/emotionless-genius-naruto-fanfiction">Emotionless Genius Naruto Fanfiction</a>,
<a href="https://api.duassis.com/storage/admq/full-to-capacity---crossword-clue">Full To Capacity - Crossword Clue</a>,
<a href="https://api.duassis.com/storage/admq/metro-manila-lockdown-update-today">Metro Manila Lockdown Update Today</a>,
<a href="https://api.duassis.com/storage/admq/niki-lauda-before-and-after-crash">Niki Lauda Before And After Crash</a>,
<a href="https://api.duassis.com/storage/admq/lord-of-the-rings-suitable-for-8-year-old">Lord Of The Rings Suitable For 8 Year Old</a>,
<a href="https://api.duassis.com/storage/admq/hockey-victoria-login">Hockey Victoria Login</a>,
";s:7:"expired";i:-1;}
Mini Shell